Investors of Rocket Pharmaceuticals Alerted to Class Action Lawsuit Amid Allegations of Securities Fraud
In a recent development, Levi & Korsinsky, LLP has informed investors of Rocket Pharmaceuticals, Inc. about a prospective class action lawsuit linked to significant claims of securities fraud. This lawsuit targets investors adversely affected between September 17, 2024, and May 26, 2025.
The class action aims to recover losses sustained by investors who purchased Rocket Pharmaceuticals' securities during the specified period. The rationale behind the lawsuit notes that the defendants allegedly made excessively favorable statements about the company while simultaneously withholding critical adverse information concerning the safety and clinical trial protocols of RP-A501, a key product of the company.
Specifically, the complaint alleges that Rocket’s leadership failed to disclose serious adverse events (SAEs) related to the clinical trials, including the death of some participants. Notably, prior to the reports of these dangers, Rocket revised the trial protocols without informing shareholders, which constitutes a significant breach of trust and disclosure obligations to investors.
The turning point for many investors arrived on May 27, 2025, when Rocket Pharmaceuticals announced that the FDA had placed a clinical hold on its RP-A501 Phase 2 pivotal study after a participant suffered a SAEs, which resulted in death. This announcement followed a crucial amendment to the treatment regimen that had not been communicated to shareholders at the time. The trials had shown problems relating to the safety of RP-A501, which was starkly inconsistent with the optimistic portrayal conveyed to investors.
As a result of this revelation, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, marking a steep 37% decline in a mere two trading sessions. This sharp drop can be seen as a direct response to the uncovered realities of the clinical trial outcomes that sharply contradicted the prior public communications from the company.
For affected investors, there is a critical deadline approaching. Those who suffered losses related to Rocket Pharmaceuticals' stocks during the defined period must file for lead plaintiff status by August 11, 2025. Importantly, joining this class action entails no out-of-pocket costs or fees for class members.
Levi & Korsinsky is a seasoned law firm with a strong track record in securing settlements for shareholders in similar cases. With over 20 years of experience and recognized as one of the top securities litigation firms in the United States for seven consecutive years, they exemplify reliability for aggrieved investors.
Those interested in obtaining more information or pursuing claims can reach out to Joseph E. Levi, Esq. via email or phone. They can also access detailed information through the firm's dedicated links.
The Basis of the Lawsuit
The class action aims to recover losses sustained by investors who purchased Rocket Pharmaceuticals' securities during the specified period. The rationale behind the lawsuit notes that the defendants allegedly made excessively favorable statements about the company while simultaneously withholding critical adverse information concerning the safety and clinical trial protocols of RP-A501, a key product of the company.
Specifically, the complaint alleges that Rocket’s leadership failed to disclose serious adverse events (SAEs) related to the clinical trials, including the death of some participants. Notably, prior to the reports of these dangers, Rocket revised the trial protocols without informing shareholders, which constitutes a significant breach of trust and disclosure obligations to investors.
Recent Developments
The turning point for many investors arrived on May 27, 2025, when Rocket Pharmaceuticals announced that the FDA had placed a clinical hold on its RP-A501 Phase 2 pivotal study after a participant suffered a SAEs, which resulted in death. This announcement followed a crucial amendment to the treatment regimen that had not been communicated to shareholders at the time. The trials had shown problems relating to the safety of RP-A501, which was starkly inconsistent with the optimistic portrayal conveyed to investors.
As a result of this revelation, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, marking a steep 37% decline in a mere two trading sessions. This sharp drop can be seen as a direct response to the uncovered realities of the clinical trial outcomes that sharply contradicted the prior public communications from the company.
What Investors Should Do
For affected investors, there is a critical deadline approaching. Those who suffered losses related to Rocket Pharmaceuticals' stocks during the defined period must file for lead plaintiff status by August 11, 2025. Importantly, joining this class action entails no out-of-pocket costs or fees for class members.
Why Choose Levi & Korsinsky?
Levi & Korsinsky is a seasoned law firm with a strong track record in securing settlements for shareholders in similar cases. With over 20 years of experience and recognized as one of the top securities litigation firms in the United States for seven consecutive years, they exemplify reliability for aggrieved investors.
Those interested in obtaining more information or pursuing claims can reach out to Joseph E. Levi, Esq. via email or phone. They can also access detailed information through the firm's dedicated links.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.